ÂÜÀòÂÒÂ×

John Smither brings extensive financial and operating management experience to NewAmsterdam Pharma's Board of Directors. Most recently, he served as the Chief Financial Officer (CFO) at Arcutis Biotherapeutics, where he was responsible for all financial aspects, including leading the company’s successful initial public offering and two capital raises. Prior to joining Arcutis, Mr. Smither acted as CFO for Sienna Biopharmaceuticals, and as interim CFO for Kite Pharma during its integration with Gilead. He has also served as CFO of Unity Biotechnology and of Kythera Biopharmaceuticals. In his various CFO positions, John oversaw multiple private and public financing rounds, including Kythera’s initial public offering, and initial IPO preparations at Sienna. Additionally, John has previously served on the Boards of several biopharmaceutical companies including Achaogen, Inc. and Dompé Biotec, SpA. He also currently serves as Director at both eFFECTOR Therapeutics and Applied Molecular Transport.